{"denoms":[{"counts":[{"groupId":"BG000","value":"121"},{"groupId":"BG001","value":"638"},{"groupId":"BG002","value":"759"}],"units":"Participants"}],"groups":[{"description":"Participants with chronic kidney disease and a diagnosis of secondary hyperparathyroidism, and who were not yet on dialysis received paricalcitol injection or capsules, on an on-label basis in an everyday setting. Participants were observed for 12 months.","id":"BG000","title":"Paricalcitol Pre-dialysis Group"},{"description":"Participants with chronic kidney disease and a diagnosis of secondary hyperparathyroidism, and on dialysis received paricalcitol injection or capsules, on an on-label basis in an everyday setting. Participants were observed for 12 months.","id":"BG001","title":"Paricalcitol Dialysis Group"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"13.9","value":"64.2"},{"groupId":"BG001","spread":"14.9","value":"62.5"},{"groupId":"BG002","spread":"14.8","value":"62.8"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"47"},{"groupId":"BG001","value":"291"},{"groupId":"BG002","value":"338"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"74"},{"groupId":"BG001","value":"347"},{"groupId":"BG002","value":"421"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"36.0","value":"39.3"},{"groupId":"BG001","spread":"61.1","value":"71.2"},{"groupId":"BG002","spread":"59.6","value":"67.5"}]}]}],"description":"Duration of Chronic Kidney Disease until the start of the study","dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Duration of Chronic Kidney Disease","unitOfMeasure":"months"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"20.6","value":"17.7"},{"groupId":"BG001","spread":"36.6","value":"43.9"},{"groupId":"BG002","spread":"35.8","value":"39.5"}]}]}],"description":"Duration of Secondary Hyperparathyroidism until the start of the study","dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Duration of Secondary Hyperparathyroidism","unitOfMeasure":"months"}],"populationDescription":"A total of 761 participants were enrolled in the study, however 2 participants lacked information necessary for assignment to one of the analysis groups. Hence, analysis was conducted with 759 participants."}